Natalia Tovar
Research Subjects
Natalia Tovar has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Fernández de Larrea
Hospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
93 shared publications - Aina Oliver-Caldés
Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona Barcelona Spain
83 shared publications - David F. Moreno
Amyloidosis and Myeloma Unit, Department of Hematology Hospital Clínic de Barcelona, University of Barcelona Barcelona Spain
83 shared publications - Anthony Matthew Battram
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
81 shared publications - Laura Rosiñol
Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain
78 shared publications - Luis Gerardo Rodríguez-Lobato
Hematology Department, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
78 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Covariate balance before and after IPTW
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Covariate balance before and after IPTW
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
IPTW-weighted Kaplan-Meier estimates at 12 months
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
IPTW-weighted Kaplan-Meier estimates at 12 months
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Patient flow and applied analyses. Top panel – entire cohort. Middle panel – cohort for the primary multistate models and landmark analyses. Lower panel – IPTW analysis.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Patient flow and applied analyses. Top panel – entire cohort. Middle panel – cohort for the primary multistate models and landmark analyses. Lower panel – IPTW analysis.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Observed survival according to first immunotherapy
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Observed survival according to first immunotherapy
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
RPSFTM-adjusted overall survival by initial treatment modality. RPSFTM-adjusted overall survival. The observed CAR T-first curve (solid dark blue) is compared with the observed BsAb-first curve (dashed crimson) and the RPSFTM-adjusted BsAb-first curve (solid orange). The adjusted curve represents the counterfactual survival of BsAb-first patients had no treatment switching to CAR T occurred, estimated using rank-preserving structural failure time modeling with g-estimation. Number at risk tables are shown below each panel. All estimates are descriptive and should be interpreted in the context of non-randomized treatment allocation and the assumptions of the RPSFTM framework.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
RPSFTM-adjusted overall survival by initial treatment modality. RPSFTM-adjusted overall survival. The observed CAR T-first curve (solid dark blue) is compared with the observed BsAb-first curve (dashed crimson) and the RPSFTM-adjusted BsAb-first curve (solid orange). The adjusted curve represents the counterfactual survival of BsAb-first patients had no treatment switching to CAR T occurred, estimated using rank-preserving structural failure time modeling with g-estimation. Number at risk tables are shown below each panel. All estimates are descriptive and should be interpreted in the context of non-randomized treatment allocation and the assumptions of the RPSFTM framework.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Sensitivity analysis for 6-month landmark.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Sensitivity analysis for 6-month landmark.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
IPTW-adjusted hazard ratios (univariable)
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
IPTW-adjusted hazard ratios (univariable)
- Open Access
- 12 June 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (5) , 697-710
Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
We explored single or consecutive CAR-T and BsAb treatment modalities as correlates of clinical outcomes, by complementary bias-correction analysis of a retrospective multicenter study of 640 patients with relapsed/refractory multiple myeloma. Sequential use of both modalities appeared to yield the most favorable survival trajectories. Initiating treatment with CAR-T (ide-cel, cilta-cel, cesni-cel) was associated with longer remission. However, mortality from early progression was similar regardless of initial modality, suggesting that resistance may negate initial efficacy difference. On product level, the benefit of CAR-T appeared to be driven by cilta-cel and cesni-cel, whereas BsAb showed at least comparable outcomes to ide-cel. These exploratory findings highlight the critical importance of treatment sequencing in optimizing long-term outcomes and underscore the need for equitable and timely access to both modalities across healthcare systems.
- 12 June 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (5) , 697-710
Open AccessOutcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
We explored single or consecutive CAR-T and BsAb treatment modalities as correlates of clinical outcomes, by complementary bias-correction analysis of a retrospective multicenter study of 640 patients with relapsed/refractory multiple myeloma. Sequential use of both modalities appeared to yield the most favorable survival trajectories. Initiating treatment with CAR-T (ide-cel, cilta-cel, cesni-cel) was associated with longer remission. However, mortality from early progression was similar regardless of initial modality, suggesting that resistance may negate initial efficacy difference. On product level, the benefit of CAR-T appeared to be driven by cilta-cel and cesni-cel, whereas BsAb showed at least comparable outcomes to ide-cel. These exploratory findings highlight the critical importance of treatment sequencing in optimizing long-term outcomes and underscore the need for equitable and timely access to both modalities across healthcare systems.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
ScFv Sequences and antibody panels
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
ScFv Sequences and antibody panels